CAVAZZONI, Andrea

CAVAZZONI, Andrea  

Dipartimento di Medicina e Chirurgia  

Mostra records
Risultati 1 - 20 di 140 (tempo di esecuzione: 0.011 secondi).
Titolo Data di pubblicazione Autore(i) File
5-benzylidene-hydantoin UPR 1024 acts as EGFR inhibitor and induces DNA damage in A549 NSCLC cell line 1-gen-2007 Cavazzoni, Andrea; Galetti, Maricla; Alfieri, Roberta; Carmi, C; Zuliani, Valentina; Fumarola, C; Bonelli, Mara; Frazzi, R; Mor, Marco; Petronini, Pier Giorgio
5-Benzylidene-hydantoins as new EGFR inhibitors with antiproliferative activity 1-gen-2006 Carmi, Caterina; Cavazzoni, Andrea; Zuliani, Valentina; Lodola, Alessio; Bordi, Fabrizio; Plazzi, Pier Vincenzo; Alfieri, Roberta; Petronini, Pier Giorgio; Mor, Marco
5-benzylidene-hydantoins as new inhibitors of cell proliferation 1-gen-2006 Cavazzoni, Andrea; Alfieri, Roberta; Galetti, M; Carmi, C; Zuliani, Valentina; Mor, Marco; Petronini, Pier Giorgio
5-Benzylidene-hydantoins: synthesis and antiproliferative activity on A549 lung cancer cell line 1-gen-2009 Zuliani, Valentina; Carmi, Caterina; Rivara, Mirko; Fantini, M; Lodola, Alessio; Vacondio, Federica; Bordi, Fabrizio; Plazzi, Pier Vincenzo; Cavazzoni, Andrea; Galetti, Maricla; Alfieri, Roberta; Petronini, Pier Giorgio; Mor, Marco
Aberrant expression of PTEN in squamous lung cancer cells: molecular analysis and impact on the synergistic combination of the targeted therapy with BKM120 and Defactinib 1-gen-2015 Cavazzoni, A; Giovannetti, E; Alfieri, R; Caraffini, Veronica; Tiseo, M; Sciarrillo, R; Ardizzoni, A; Petronini, Pg.
Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion 1-gen-2019 La Monica, S.; Minari, R.; Cretella, D.; Bonelli, M.; Fumarola, C.; Cavazzoni, A.; Galetti, M.; Digiacomo, G.; Riccardi, F.; Petronini, P. G.; Tiseo, M.; Alfieri, R.
Anti-proliferative and pro-apoptotic effects of Sorafenib in breast cancer cells in vitro. 1-gen-2010 Fumarola, Claudia; Bonelli, Mara; K., Airoud; Alfieri, Roberta; Cavazzoni, Andrea; Galetti, Maricla; LA MONICA, Silvia; D., Generali; Petronini, Pier Giorgio
Anti-proliferative effect of combining Letrozole with Sorafenib in MCF-7/Arom-1 breast cancer cells 1-gen-2008 Bonelli, Mara; Fumarola, Claudia; Alfieri, Roberta; Gatti, Rita; Belletti, Silvana; LA MONICA, Silvia; Galetti, M; Cavazzoni, Andrea; Frazzi, A; Bottini, A; Bergamini, L; Lynch, M; Harris, Al; Fox, Sb; Generali, Dg
Anti-proliferative effect of induced Fhit expression in non small cell lung cancer cell line (Calu-1) 1-gen-2003 Cavazzoni, Andrea; Galetti, Maricla; Fumarola, F; Carbognani, Paolo; Alfieri, Roberta; Rusca, M. AND PETRONINI P. G.
Anti-proliferative effect of letrozole and sorafenib in MCF-7/AROM-1 breast cancer cells 1-gen-2008 Bonelli, Mara; Fumarola, Claudia; Alfieri, Roberta; LA MONICA, Silvia; Cavazzoni, Andrea; Galetti, M; Gatti, Rita; Belletti, Silvana; Bottini, A; Generali, D; Petronini, Pier Giorgio
Anti-proliferative effects of copper(II) complexes with hydroxyquinoline-thiosemicarbazone ligands 1-gen-2017 Rogolino, Dominga; Cavazzoni, Andrea; Gatti, Anna; Tegoni, Matteo; Pelosi, Giorgio; Verdolino, Vincenzo; Fumarola, Claudia; Cretella, Daniele; Petronini, Pier Giorgio; Carcelli, Mauro
The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells 1-gen-2018 Cretella, Daniele; Ravelli, Andrea; Fumarola, Claudia; LA MONICA, Silvia; Digiacomo, Graziana; Cavazzoni, Andrea; Alfieri, Roberta; Biondi, Alessandra; Generali, Daniele; Bonelli, Mara; Petronini, Pier Giorgio
Antibacterial and antitumor activity of tetracyclic fluoroquinolones with pyrido[2,3-a]carbazole structure 1-gen-2010 Zani, Franca; Vicini, Paola; Cavazzoni, Andrea; S., Al Trawneh; J., Zahra; M., Kamal; M., El Abadelah
Antiproliferative and proapototic effects of a new combi-molecule on non small cell lung cancer cell lines 1-gen-2007 Alfieri, Roberta; Cavazzoni, Andrea; Carmi, Caterina; M., Galetti; Zuliani, Valentina; Fumarola, Claudia; Mor, Marco; Petronini, Pier Giorgio
Balancing reactivity and antitumor activity: heteroarylthioacetamide derivatives as potent and time-dependent inhibitors of EGFR 1-gen-2019 Castelli, R; Bozza, N; Cavazzoni, A; Bonelli, M; Vacondio, F; Ferlenghi, F; Callegari, D; Silva, C; Rivara, S; Lodola, A; Digiacomo, G; Fumarola, C; Alfieri, R; Petronini, Pg; Mor, M.
Biological hallmarks and new therapeutic approaches for the treatment of pdac 1-gen-2021 Digiacomo, G.; Volta, F.; Garajova, I.; Balsano, R.; Cavazzoni, A.
Cancer of Unknown Primary: novel therapeutic opportunities from patient-derived cell cultures and in vivo models 1-gen-2021 Laprovitera, N; Fumarola, C; Porcellini, E; Cairo, S; Gallerani, G; Gelsomino, F; Salamon, I; Naddeo, M; Ardizzoni, A; Cavazzoni, A.; Ferracin, M.
CDK4/6 inhibitors overcome resistance to osimertinib in NSCLC cell lines independently from resistance mechanisms 1-gen-2019 Cretella, D; La Monica, S; Minari, R; Cavazzoni, A; Galetti, M; Petronini, P. G.; Tiseo, M; Alfieri, R.
Cell culture studies of polysaccharide films loaded with cisplatin for the loco-regional therapy of malignant pleural mesothelioma 1-gen-2008 Cavazzoni, Andrea; Sonvico, Fabio; Barbieri, S; Ampollini, Luca; Rossi, Alessandra; Gussago, F; Colombo, G; Petronini, Pier Giorgio; Colombo, Paolo; Carbognani, Paolo
Changes in glucose uptake after erlotinib treatment in NSCLC cell lines: a predictive and prognostic value? 1-gen-2012 Caffarra, C; Fumarola, C; Cavazzoni, A; Alfieri, R; Petronini, Pg.